Deals
Freezes Paramount's $110B Warner Bros Buy
DOJ cleared Paramount's $110 billion buy of Warner Bros. Discovery, then 12 states froze it anyway, days before an August 3 injunction hearing.
Deals — Page 2
M&A, fundraising, IPOs, and bankruptcies in regulated industries.
Deals
Bought PolyPeptide for $1.8B in Samsung's Peptide Push
Samsung Biologics pays just a 6% premium for PolyPeptide, its second buyout in eight months and Korea's largest-ever biopharma deal.
Deals
BlossomHill Files for IPO to Chase AstraZeneca
BlossomHill is asking public markets for $100M to challenge AstraZeneca's $7.25B-a-year Tagrisso, backed by nothing past phase 1/2 data.
Deals
Bought Comerica for $10.9B, Fifth Third Nears $850M Win
Comerica's board took a 20% premium in October. Now Fifth Third's $850 million synergy bet gets tested over the Labor Day weekend conversion.
Deals
Lakestar Closes $300M Resilience Fund for EU Defense
Lakestar closed a $300 million fund betting Brussels' sovereignty anxiety turns into procurement revenue for Helsing and Auterion.
Deals
Cut 87% of Arcellx Staff After $7.8B Gilead Buy
Gilead paid $7.8B for Arcellx's CAR-T pipeline, then eliminated 192 of its 220 employees, 87% of the entire staff, within weeks of closing.
Deals
Buys Carolina Bank & Trust for $166M
First Bank is paying $166 million for a privately held SC lender with no public price to set a premium. It adds $831M in assets and 14 branches.
Deals
Attovia Files IPO to Chase Nemluvio's $4B Market
Attovia wants public money for a drug that hasn't started phase 2, betting it can unseat a franchise Galderma just repriced to $4B.
Deals
Buys TriCo: First Hawaiian's $2B Stock Deal
First Hawaiian is paying $63.12 a share in stock for TriCo, its second attempt at a mainland network since losing one to BMO in 2023.
Deals
Spero Pays Up to $1.1B for Innovent's CD40L Drug
Spero can't match AbbVie's $10.9B checkbook, so it mortgaged an FDA-approved antibiotic's royalties to fund a $1.1B autoimmune bet instead.
Deals
AstraZeneca Pays $1.5B for Dizal's Zegfrovy
AstraZeneca pays $1.5B for Dizal's Zegfrovy, skips the Greater China carve-out, and bets on frontline data it hasn't won approval for yet.
Deals
Apnimed Files for IPO After $100M Shionogi Exit
Apnimed banked $100M from Shionogi in March, then filed a blank-check IPO to fund its sleep apnea pill still awaiting an FDA verdict.
Deals
Brockman Grabs OpenAI's No. 2 Job as Simo Exits
OpenAI won't replace Fidji Simo. Greg Brockman just inherited her job, her budget line, and the products that actually make OpenAI money.
Deals
Nu Clears CNBV Hurdle, Gets 30 Days to Convert
Nu spent six years chasing a Mexican bank charter, nine months behind Revolut. The 30-day countdown to full bank status starts now.
Deals
Oregon Moves to Delay Paramount's $110B WBD Deal
Oregon says Paramount is racing to close its $110B Warner Bros. Discovery buy before regulators can finish digging through the records.
Deals
House Panel Clears Earned Wage Access Bill 31-23
A 31-23 party-line vote pushes a federal EWA framework to the House floor, stripping states of power to call these wage advances loans.
Deals
Thrive Holdings Raises $2B to Buy Up Service Firms
Altimeter, D1 and SoftBank just wrote the first outside check to Josh Kushner's AI roll-up vehicle. No price or premium was disclosed.
Deals
SK Hynix Files for $29B Nasdaq Listing
SK Hynix's $29 billion Nasdaq bid would top Alibaba's 2014 IPO record, betting Wall Street pays more for AI exposure than Seoul does.
Deals
Novartis Buys Myricx for $1.1B in ADC Push
Novartis just paid $1.1B for a biotech whose lead drugs have never touched a human patient. The math on that bet doesn't look cheap.
Deals
Starling Cuts 130 Jobs After Profit Slips 3%
Starling axed 130 jobs right after profits fell and a £29 million FCA fine for "shockingly lax" crime controls still weighs on the ledger.
